- Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors
-
Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.
- Joncour, Agnès,Desroy, Nicolas,Housseman, Christopher,Bock, Xavier,Bienvenu, Natacha,Cherel, La?titia,Labeguere, Virginie,Peixoto, Christophe,Annoot, Denis,Lepissier, Luce,Heiermann, J?rg,Hengeveld, Willem Jan,Pilzak, Gregor,Monjardet, Alain,Wakselman, Emanuelle,Roncoroni, Veronique,Le Tallec, Sandrine,Galien, René,David, Christelle,Vandervoort, Nele,Christophe, Thierry,Conrath, Katja,Jans, Mia,Wohlkonig, Alexandre,Soror, Sameh,Steyaert, Jan,Touitou, Robert,Fleury, Damien,Vercheval, Lionel,Mollat, Patrick,Triballeau, Nicolas,Van Der Aar, Ellen,Brys, Reginald,Heckmann, Bertrand
-
p. 7371 - 7392
(2017/09/23)
-
- Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography
-
Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors. We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent molecular dynamics simulations. Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compound. In addition, respectable levels of antiproliferative activity for these compounds have been obtained. Finally, the binding mode predicted by docking and molecular dynamics simulations is validated by solving the crystal structures of three members of this chemical class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.
- Lafleur, Karine,Dong, Jing,Huang, Danzhi,Caflisch, Amedeo,Nevado, Cristina
-
-
- Novel 5-HT2A receptor ligands
-
Compounds of formula I: are antagonists of the human 5-HT2A receptor, and hence useful in treatment or prevention of a variety of neurological conditions.
- -
-
Page/Page column 9
(2010/02/11)
-